Cantor Fitzgerald Estimates MRK FY2026 Earnings

Key Takeaways:

• Cantor Fitzgerald releases new FY2026 EPS estimates for Merck & Co., Inc.
• Analyst C. Gould predicts an EPS of $9.62 for Merck in 2026.
• The research note was issued on Monday, June 9th.
• Merck & Co., Inc. is listed on the NYSE under the ticker symbol MRK.
• The estimates were reported by American Banking News on June 11th, 2025.

Cantor Fitzgerald Releases New EPS Estimates for Merck

Research analysts at Cantor Fitzgerald have released their fiscal year 2026 earnings per share (EPS) estimates for pharmaceutical giant Merck & Co., Inc. In a research note issued to investors on Monday, June 9th, analyst C. Gould predicts that the company will post an EPS of $9.62 for the year.

Analyst C. Gould Predicts $9.62 EPS

The projection by analyst C. Gould provides valuable insight into Merck’s anticipated financial performance. The estimated EPS of $9.62 suggests significant earnings, which is information of interest to investors and market observers alike.

Research Note Issued on June 9th

The estimates were detailed in a research note distributed to investors on June 9th. Timely analyst reports such as this one can impact investor sentiment and contribute to stock market movements.

Merck’s Market Presence

Merck & Co., Inc., trading on the New York Stock Exchange under the ticker symbol MRK, is a leading player in the pharmaceutical industry. Known for its contributions to medicine and healthcare, Merck’s financial health is closely watched by stakeholders.

Report Covered by American Banking News

These new estimates were reported by American Banking News on June 11th, 2025, providing the public with the latest insights from Cantor Fitzgerald’s analysts.

Note: All information presented is sourced directly from the original news feed content provided.